Kaul was formely CEO of Cloud Diagnostics LLC, a healthcare IT distribution company he founded in 2009. In June 2010, Biosign acquired the assets of Cloud Diagnostics, and from July 2010 to June 2011, Kaul served as EVP of Biosign Technologies, where he focused on international sales & business development. He then served in a consulting capacity for Biosign Technologies.
Kaul holds a B.Sc. in Biology, Chemistry, History from the University of Alberta.
Kaul has also previously served as Director of Operations at Luna Technologies International Inc, and COO for ARA Safety Inc. (where he was COO).
In connection with appointment, Biosign Technologies has granted 2,000,000 stock options to Kaul. These options expire in 5 years and have an exercise price of $0.10 per share with 500,000 options vesting immediately, 500,000 options on the first year anniversary, 500,000 options on the second year anniversary of the date of grant, and 500,000 options upon the attainment of specified sales-related milestones.
“The board is very pleased to welcome Robert Kaul back to the Company as Chief Executive Officer. During his tenure as EVP, Robert was successful at negotiating and managing distribution relationships with our partners in Germany, the Middle East and Canada. We anticipate that his many years of experience in the U.S. market as well as his track record as an entrepreneur will result in a strong new direction for our Company,” commented John Rizvi, Chairman of Biosign Technologies.
Biosign Technologies also announced Dr. Scott Jenkins, Biosign’s former CEO, will also resign as director but remain an advisor in a consulting capacity.
Biosign Technologies’ board will consist of Rizvi, Zoheb Rizvi, Jason Meretsky, Alfonse D’Amato, and Kaul.